(Q51774820)

12 April 2018

title

Reduced elimination of IgG antibodies by engineering the variable region. (English)

1 reference

12 April 2018

1 reference

T Igawa

1

1 reference

12 April 2018

H Tsunoda

2

1 reference

12 April 2018

T Tachibana

3

1 reference

12 April 2018

A Maeda

4

1 reference

12 April 2018

F Mimoto

5

1 reference

12 April 2018

C Moriyama

6

1 reference

12 April 2018

M Nanami

7

1 reference

12 April 2018

Y Sekimori

8

1 reference

12 April 2018

Y Nabuchi

9

1 reference

12 April 2018

Y Aso

10

1 reference

12 April 2018

K Hattori

11

1 reference

12 April 2018

publication date

15 February 2010

1 reference

12 April 2018

Protein Engineering Design and Selection

published in

1 reference

12 April 2018

volume

23

1 reference

12 April 2018

issue

5

1 reference

12 April 2018

page(s)

385-392

1 reference

12 April 2018

Improving antibody binding affinity and specificity for therapeutic development

cites work

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ009

Therapeutic antibodies for human diseases at the dawn of the twenty-first century

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ009

Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ009

Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ009

Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ009

Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ009

Increasing the serum persistence of an IgG fragment by random mutagenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ009

SDR grafting of a murine antibody using multiple human germline templates to minimize its immunogenicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ009

Engineered human IgG antibodies with longer serum half-lives in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ009

An engineered human IgG1 antibody with longer serum half-life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ009

Deimmunization of monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ009

Improved renal clearance and tumor targeting of 99mTc-labeled anti-Tac monoclonal antibody Fab by chemical modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ009

A passionate kiss, then run: exocytosis and recycling of IgG by FcRn.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ009

Antibody pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ009

Monoclonal antibody "gold rush".

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ009

Antibody modeling: implications for engineering and design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ009

Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ009

Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ009

Molecular engineering and design of therapeutic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ009

Ribosome display for improved biotherapeutic molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ009

Challenges in the development of high protein concentration formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ009

Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ009

Elimination mechanisms of therapeutic monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ009

Affinity maturation by phage display

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ009

Stability engineering of antibody single-chain Fv fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZQ009

21 January 2018

Identifiers

DOI

10.1093/PROTEIN/GZQ009

1 reference

12 April 2018

1 reference

12 April 2018